Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in studies on enzyme inhibitors as drugs . Volume 2 Miscellaneous drugs / / Satya P. Gupta, editor
| Advances in studies on enzyme inhibitors as drugs . Volume 2 Miscellaneous drugs / / Satya P. Gupta, editor |
| Pubbl/distr/stampa | New York : , : Nova Biomedical, , [2017] |
| Descrizione fisica | 1 online resource (341 pages) : illustrations (some color) |
| Collana | Pharmacology - research, safety testing and regulation |
| Soggetto topico | Enzyme inhibitors |
| ISBN | 1-5361-0521-X |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910159436003321 |
| New York : , : Nova Biomedical, , [2017] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition : chymotrypsin / / Gerald W. Feigenson
| Enzyme inhibition : chymotrypsin / / Gerald W. Feigenson |
| Autore | Feigenson Gerald W. (Cornell University, USA) |
| Pubbl/distr/stampa | London, : Henry Stewart Talks, 2020 |
| Descrizione fisica | 1 online resource (1 streaming video file (46 min.) : color, sound) |
| Collana | Principles of biochemistry |
| Soggetto topico |
Chymotrypsin
Enzyme inhibitors Enzymes - Chemistry Catalysis Chymotrypsin - chemistry Chymotrypsin - metabolism Enzyme Inhibitors Enzymes - chemistry Models, Chemical |
| Formato | Videoregistrazioni  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Contents: "Efficient" enzymes -- Enzyme inhibition -- Competitive inhibition -- Non-competitive inhibition -- Irreversible inhibition -- Diagrams of enzyme mechanisms -- Chymotrypsin mechanism. |
| Record Nr. | UNINA-9910887856903321 |
Feigenson Gerald W. (Cornell University, USA)
|
||
| London, : Henry Stewart Talks, 2020 | ||
| Videoregistrazioni | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition . Environmental and biomedical applications Volume 1 / / edited by G. Baskar, K. Sathish Kumar and K. Tamilarasan
| Enzyme inhibition . Environmental and biomedical applications Volume 1 / / edited by G. Baskar, K. Sathish Kumar and K. Tamilarasan |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (321 pages) |
| Disciplina | 615.3 |
| Collana | Frontiers in Enzyme Inhibition |
| Soggetto topico | Enzyme inhibitors |
| Soggetto genere / forma | Electronic books. |
| ISBN | 981-14-6082-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910493216503321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition . Environmental and biomedical applications Volume 1 / / edited by G. Baskar, K. Sathish Kumar and K. Tamilarasan
| Enzyme inhibition . Environmental and biomedical applications Volume 1 / / edited by G. Baskar, K. Sathish Kumar and K. Tamilarasan |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (321 pages) |
| Disciplina | 615.3 |
| Collana | Frontiers in Enzyme Inhibition |
| Soggetto topico | Enzyme inhibitors |
| ISBN | 981-14-6082-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910794333303321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition . Environmental and biomedical applications Volume 1 / / edited by G. Baskar, K. Sathish Kumar and K. Tamilarasan
| Enzyme inhibition . Environmental and biomedical applications Volume 1 / / edited by G. Baskar, K. Sathish Kumar and K. Tamilarasan |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (321 pages) |
| Disciplina | 615.3 |
| Collana | Frontiers in Enzyme Inhibition |
| Soggetto topico | Enzyme inhibitors |
| ISBN | 981-14-6082-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910827356603321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition in drug discovery and development [[electronic resource] ] : the good and the bad / / edited by Chuang Lu, Albert P. Li
| Enzyme inhibition in drug discovery and development [[electronic resource] ] : the good and the bad / / edited by Chuang Lu, Albert P. Li |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley, c2010 |
| Descrizione fisica | 1 online resource (878 p.) |
| Disciplina |
615.35
615/.19 |
| Altri autori (Persone) |
LuChuang
LiA. P |
| Soggetto topico |
Enzyme inhibitors
Drug development Drugs - Metabolism |
| ISBN |
1-282-49134-2
9786612491344 0-470-53895-3 0-470-53894-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES; 1. The Drug Discovery Process; 2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors; 3. Bioanalytical Technologies in Drug Discovery; 4. Safety Biomarkers in Drug Development: Emerging Trends and Implications; 5. The Role of Drug Metabolism in Drug Discovery; 6. Applied Pharmacokinetics in Drug Discovery and Development; PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES-THE UNDESIRABLE INHIBITION
7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes8. Cytochrome P450 Induction; 9. Inhibition of Drug-Metabolizing Enzymes in the Gastrointestinal Tract and Its Influence on the Drug-Drug Interaction Prediction; 10. Enzyme Inhibition in Various In Vitro Systems; 11. Cytochrome P450 Degradation and Its Clinical Relevance; 12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition; 13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes; 14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors 15. Transporter-Xenobiotic Interactions: An Important Aspect of Drug Development Studies16. Polymorphisms of Drug Transporters and Their Clinical Implications; 17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation; 18. Predicting Interindividual Variability of Metabolic Drug-Drug Interactions: Identifying the Causes and Accounting for Them Using a Systems Approach; PART III. INHIBITION OF THE DRUG TARGET ENZYMES-THE DESIRABLE INHIBITION; 19. NF-κB: Mechanism, Tumor Biology, and Inhibitors; 20. G-Protein-Coupled Receptors as Drug Targets 21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain22. Targeting the mTOR Pathway for Tumor Therapeutics; 23. HIV-1 Protease Inhibitors as Antiretroviral Agents; INDEX |
| Record Nr. | UNINA-9910139522703321 |
| Hoboken, NJ, : John Wiley, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition in drug discovery and development [[electronic resource] ] : the good and the bad / / edited by Chuang Lu, Albert P. Li
| Enzyme inhibition in drug discovery and development [[electronic resource] ] : the good and the bad / / edited by Chuang Lu, Albert P. Li |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley, c2010 |
| Descrizione fisica | 1 online resource (878 p.) |
| Disciplina |
615.35
615/.19 |
| Altri autori (Persone) |
LuChuang
LiA. P |
| Soggetto topico |
Enzyme inhibitors
Drug development Drugs - Metabolism |
| ISBN |
1-282-49134-2
9786612491344 0-470-53895-3 0-470-53894-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES; 1. The Drug Discovery Process; 2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors; 3. Bioanalytical Technologies in Drug Discovery; 4. Safety Biomarkers in Drug Development: Emerging Trends and Implications; 5. The Role of Drug Metabolism in Drug Discovery; 6. Applied Pharmacokinetics in Drug Discovery and Development; PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES-THE UNDESIRABLE INHIBITION
7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes8. Cytochrome P450 Induction; 9. Inhibition of Drug-Metabolizing Enzymes in the Gastrointestinal Tract and Its Influence on the Drug-Drug Interaction Prediction; 10. Enzyme Inhibition in Various In Vitro Systems; 11. Cytochrome P450 Degradation and Its Clinical Relevance; 12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition; 13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes; 14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors 15. Transporter-Xenobiotic Interactions: An Important Aspect of Drug Development Studies16. Polymorphisms of Drug Transporters and Their Clinical Implications; 17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation; 18. Predicting Interindividual Variability of Metabolic Drug-Drug Interactions: Identifying the Causes and Accounting for Them Using a Systems Approach; PART III. INHIBITION OF THE DRUG TARGET ENZYMES-THE DESIRABLE INHIBITION; 19. NF-κB: Mechanism, Tumor Biology, and Inhibitors; 20. G-Protein-Coupled Receptors as Drug Targets 21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain22. Targeting the mTOR Pathway for Tumor Therapeutics; 23. HIV-1 Protease Inhibitors as Antiretroviral Agents; INDEX |
| Record Nr. | UNINA-9910830438803321 |
| Hoboken, NJ, : John Wiley, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme inhibition in drug discovery and development : the good and the bad / / edited by Chuang Lu, Albert P. Li
| Enzyme inhibition in drug discovery and development : the good and the bad / / edited by Chuang Lu, Albert P. Li |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley, c2010 |
| Descrizione fisica | 1 online resource (878 p.) |
| Disciplina |
615.35
615/.19 |
| Altri autori (Persone) |
LuChuang
LiA. P |
| Soggetto topico |
Enzyme inhibitors
Drug development Drugs - Metabolism |
| ISBN |
1-282-49134-2
9786612491344 0-470-53895-3 0-470-53894-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES; 1. The Drug Discovery Process; 2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors; 3. Bioanalytical Technologies in Drug Discovery; 4. Safety Biomarkers in Drug Development: Emerging Trends and Implications; 5. The Role of Drug Metabolism in Drug Discovery; 6. Applied Pharmacokinetics in Drug Discovery and Development; PART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES-THE UNDESIRABLE INHIBITION
7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes8. Cytochrome P450 Induction; 9. Inhibition of Drug-Metabolizing Enzymes in the Gastrointestinal Tract and Its Influence on the Drug-Drug Interaction Prediction; 10. Enzyme Inhibition in Various In Vitro Systems; 11. Cytochrome P450 Degradation and Its Clinical Relevance; 12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition; 13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes; 14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors 15. Transporter-Xenobiotic Interactions: An Important Aspect of Drug Development Studies16. Polymorphisms of Drug Transporters and Their Clinical Implications; 17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation; 18. Predicting Interindividual Variability of Metabolic Drug-Drug Interactions: Identifying the Causes and Accounting for Them Using a Systems Approach; PART III. INHIBITION OF THE DRUG TARGET ENZYMES-THE DESIRABLE INHIBITION; 19. NF-κB: Mechanism, Tumor Biology, and Inhibitors; 20. G-Protein-Coupled Receptors as Drug Targets 21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain22. Targeting the mTOR Pathway for Tumor Therapeutics; 23. HIV-1 Protease Inhibitors as Antiretroviral Agents; INDEX |
| Record Nr. | UNINA-9910877182103321 |
| Hoboken, NJ, : John Wiley, c2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme technologies : pluripotent players in discovering therapeutic agents / / edited by Hsiu-Chiung Yang, Wu-Kuang Yeh, James R. McCarthy
| Enzyme technologies : pluripotent players in discovering therapeutic agents / / edited by Hsiu-Chiung Yang, Wu-Kuang Yeh, James R. McCarthy |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2014 |
| Descrizione fisica | 1 online resource (366 p.) |
| Disciplina | 615.3 |
| Altri autori (Persone) |
YangHsiu-Chiung
YehWu-Kuang <1942-> McCarthyJ. R |
| Collana | Chemical Biology of Enzymes for Biotechnology and Pharmaceutical Applications |
| Soggetto topico |
Enzyme inhibitors
Enzymes - Pharmacokinetics Drugs - Design |
| ISBN |
1-118-73990-6
1-118-73989-2 |
| Classificazione | SCI010000 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agents; Copyright; Contents; Contributors; Preface; PART A ENZYMES - ESSENTIAL WORKHORSES IN PHARMACEUTICAL RESEARCH; 1 ASSAY TECHNOLOGIES FOR PROTEASES; I. INTRODUCTION; II. PROTEASE ACTIVITY ASSAYS; III. ASSAYS FOR SOME CLINICALLY SIGNIFICANT PROTEASES; IV. COMPUTATIONAL APPROACHES FOR PROTEASE IDENTIFICATION AND CHARACTERIZATION; 2 DISCOVERY AND DEVELOPMENT OF ISOZYME-SELECTIVE INHIBITORS INVOLVED IN LIPID METABOLISM; I. INTRODUCTION; II. DIACYLGLYCEROL ACYLTRANSFERASE (DGAT)
III. ACYL-COA: CHOLESTEROL ACYLTRANSFERASE (ACAT)IV. CONCLUSIONS AND FUTURE PERSPECTIVES; References; 3 COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT; I. INTRODUCTION; II. MECHANISM OF INHIBITION: MECHANISTIC TYPES BY PRINCIPLE OF INHIBITION; III. KINETICS: CONCEPTUAL AND EXPERIMENTAL CONSIDERATIONS; IV. SPECIFIC EXAMPLES OF COVALENT INHIBITORS; V. COVALENT ADDUCT WITH COFACTOR ALONE; VI. FULLY IRREVERSIBLE NONCOVALENT INHIBITION; VII. REVERSIBILITY AND DRUG RESISTANCE; VIII. PSEUDO-IRREVERSIBLE INHIBITION; IX. IRREVERSIBLE INHIBITORS AS TOOLS: ACTIVITY-BASED PROTEOMICS (ABP) X. MBI OF CYPsXI. THE PROBLEM OF HAPTENATION; XII. CONCLUSION; References; 4 PRECLINOMICS: ENZYME ASSAYS AND RODENT MODELS FOR METABOLIC DISEASES; I. INTRODUCTION; II. EVOLVING ENZYME ASSAYS; III. DEVELOPING NEW RAT MODEL FOR METABOLIC DISEASES; IV. ZDSD RAT: EVALUATING CURRENT DRUGS; V. EXISTING RODENT MODELS: ESTABLISHING POSITIVE CONTROLS; VI. EXISTING RODENT MODELS AND ONE CANCER PATIENT: TESTING NUTRITIONAL SUPPLEMENT (ALKA VITA); VII. CONCLUDING REMARKS; References; PART B ENZYMES - INDISPENSABLE TOOLS FOR IMPROVING DRUGGABILITY; 5 ENZYMES AND TARGETED ACTIVATION OF PRODRUGS I. INTRODUCTIONII. ENDOGENOUS ENZYMES; III. NONENDOGENOUS ENZYMES; IV. CONCLUDING REMARKS; References; 6 EVOLUTION OF AN ORALLY ACTIVE PRODRUG OF GEMCITABINE; I. INTRODUCTION; II. PREPARATION OF GEMCITABINE PRODRUGS; III. ADVANTAGE OF CYCLOPROPYL ESTER PRODRUGS; IV. ISSUES WITH CYCLOPROPYL ESTERS OF GEMCITABINE; V. ALTERNATIVE PRODRUGS OF GEMCITABINE; VI. CO-CRYSTALS OF VALPROATE AMIDE OF GEMCITABINE; VII. STABILITY OF VALPROATE AMIDE PRODRUG; VIII. BIOAVAILABILITY OF AMIDE PRODRUG; IX. ANTITUMOR ACTIVITY OF PRODRUG; X. SUMMARY; References 7 ENZYMATICALLY ACTIVATED PHOSPHATE AND PHOSPHONATE PRODRUGSI. INTRODUCTION; II. PHOSPHATE GROUP USED FOR SOLUBILITY ENHANCEMENT; III. PHOSPHATE AND PHOSPHONATE PRODRUGS; IV. CONCLUSIONS; References; PART C ENZYMES - POWERFUL WEAPONS FOR CORRECTING NATURE ' S ERRORS; 8 TREATMENT OPTIONS FOR MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER'S SYNDROME); I. INTRODUCTION; II. HISTORY; III. BIOCHEMISTRY; IV. GENETICS; V. CLINICAL MANIFESTATION; VI. MANAGEMENT AND TREATMENT; VII. FUTURE PERSPECTIVES; References; 9 ENZYME REPLACEMENT THERAPY FOR FABRY DISEASE; I. INTRODUCTION II. THE STRUCTURE AND CATALYTIC MECHANISMS OF HUMAN ALPHA-GALACTOSIDASE A |
| Record Nr. | UNINA-9910138987203321 |
| Hoboken, New Jersey : , : Wiley, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Enzyme technologies : pluripotent players in discovering therapeutic agents / / edited by Hsiu-Chiung Yang, Wu-Kuang Yeh, James R. McCarthy
| Enzyme technologies : pluripotent players in discovering therapeutic agents / / edited by Hsiu-Chiung Yang, Wu-Kuang Yeh, James R. McCarthy |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2014 |
| Descrizione fisica | 1 online resource (366 p.) |
| Disciplina | 615.3 |
| Altri autori (Persone) |
YangHsiu-Chiung
YehWu-Kuang <1942-> McCarthyJ. R |
| Collana | Chemical Biology of Enzymes for Biotechnology and Pharmaceutical Applications |
| Soggetto topico |
Enzyme inhibitors
Enzymes - Pharmacokinetics Drugs - Design |
| ISBN |
1-118-73990-6
1-118-73989-2 |
| Classificazione | SCI010000 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agents; Copyright; Contents; Contributors; Preface; PART A ENZYMES - ESSENTIAL WORKHORSES IN PHARMACEUTICAL RESEARCH; 1 ASSAY TECHNOLOGIES FOR PROTEASES; I. INTRODUCTION; II. PROTEASE ACTIVITY ASSAYS; III. ASSAYS FOR SOME CLINICALLY SIGNIFICANT PROTEASES; IV. COMPUTATIONAL APPROACHES FOR PROTEASE IDENTIFICATION AND CHARACTERIZATION; 2 DISCOVERY AND DEVELOPMENT OF ISOZYME-SELECTIVE INHIBITORS INVOLVED IN LIPID METABOLISM; I. INTRODUCTION; II. DIACYLGLYCEROL ACYLTRANSFERASE (DGAT)
III. ACYL-COA: CHOLESTEROL ACYLTRANSFERASE (ACAT)IV. CONCLUSIONS AND FUTURE PERSPECTIVES; References; 3 COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT; I. INTRODUCTION; II. MECHANISM OF INHIBITION: MECHANISTIC TYPES BY PRINCIPLE OF INHIBITION; III. KINETICS: CONCEPTUAL AND EXPERIMENTAL CONSIDERATIONS; IV. SPECIFIC EXAMPLES OF COVALENT INHIBITORS; V. COVALENT ADDUCT WITH COFACTOR ALONE; VI. FULLY IRREVERSIBLE NONCOVALENT INHIBITION; VII. REVERSIBILITY AND DRUG RESISTANCE; VIII. PSEUDO-IRREVERSIBLE INHIBITION; IX. IRREVERSIBLE INHIBITORS AS TOOLS: ACTIVITY-BASED PROTEOMICS (ABP) X. MBI OF CYPsXI. THE PROBLEM OF HAPTENATION; XII. CONCLUSION; References; 4 PRECLINOMICS: ENZYME ASSAYS AND RODENT MODELS FOR METABOLIC DISEASES; I. INTRODUCTION; II. EVOLVING ENZYME ASSAYS; III. DEVELOPING NEW RAT MODEL FOR METABOLIC DISEASES; IV. ZDSD RAT: EVALUATING CURRENT DRUGS; V. EXISTING RODENT MODELS: ESTABLISHING POSITIVE CONTROLS; VI. EXISTING RODENT MODELS AND ONE CANCER PATIENT: TESTING NUTRITIONAL SUPPLEMENT (ALKA VITA); VII. CONCLUDING REMARKS; References; PART B ENZYMES - INDISPENSABLE TOOLS FOR IMPROVING DRUGGABILITY; 5 ENZYMES AND TARGETED ACTIVATION OF PRODRUGS I. INTRODUCTIONII. ENDOGENOUS ENZYMES; III. NONENDOGENOUS ENZYMES; IV. CONCLUDING REMARKS; References; 6 EVOLUTION OF AN ORALLY ACTIVE PRODRUG OF GEMCITABINE; I. INTRODUCTION; II. PREPARATION OF GEMCITABINE PRODRUGS; III. ADVANTAGE OF CYCLOPROPYL ESTER PRODRUGS; IV. ISSUES WITH CYCLOPROPYL ESTERS OF GEMCITABINE; V. ALTERNATIVE PRODRUGS OF GEMCITABINE; VI. CO-CRYSTALS OF VALPROATE AMIDE OF GEMCITABINE; VII. STABILITY OF VALPROATE AMIDE PRODRUG; VIII. BIOAVAILABILITY OF AMIDE PRODRUG; IX. ANTITUMOR ACTIVITY OF PRODRUG; X. SUMMARY; References 7 ENZYMATICALLY ACTIVATED PHOSPHATE AND PHOSPHONATE PRODRUGSI. INTRODUCTION; II. PHOSPHATE GROUP USED FOR SOLUBILITY ENHANCEMENT; III. PHOSPHATE AND PHOSPHONATE PRODRUGS; IV. CONCLUSIONS; References; PART C ENZYMES - POWERFUL WEAPONS FOR CORRECTING NATURE ' S ERRORS; 8 TREATMENT OPTIONS FOR MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER'S SYNDROME); I. INTRODUCTION; II. HISTORY; III. BIOCHEMISTRY; IV. GENETICS; V. CLINICAL MANIFESTATION; VI. MANAGEMENT AND TREATMENT; VII. FUTURE PERSPECTIVES; References; 9 ENZYME REPLACEMENT THERAPY FOR FABRY DISEASE; I. INTRODUCTION II. THE STRUCTURE AND CATALYTIC MECHANISMS OF HUMAN ALPHA-GALACTOSIDASE A |
| Record Nr. | UNINA-9910814431703321 |
| Hoboken, New Jersey : , : Wiley, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Enzyme inhibitors
(19)
- Enzyme Inhibitors (4)
- Biochemistry (3)
- Bioinorganic chemistry (3)
- Drug development (3)